Agios Announces FDA Approval of PYRUKYND (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
An exciting new event surrounding this announcement is in the works for May of 2022! Stay tuned!
See attachments for more info prior to the event.
PYRUKYND Approval PR_02.17.2022
.pdf
Download PDF • 269KB
PYRUKYND Label
.pdf
Download PDF • 322KB